Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers CEO bought $110K in common stock
- FDA accepts Bristol Myers’ sBLA for Opdivo plus Yervoy
- Bristol-Myers Squibb: Balancing Growth and Challenges Amidst Market Dynamics – A Hold Recommendation
- Bristol-Myers Squibb: Promising Growth Amidst Legacy Challenges and Policy Headwinds
- Bristol Myers announces OS from Phase 3 CheckMate -816 study